Cost-effectiveness of pertussis booster vaccination in the Netherlands.

Cost-effectiveness of pertussis booster vaccination in the Netherlands.

The aim of the current study is to estimate the epidemiological and economical consequences of several extended pertussis booster vaccination strategies and to explore the impact of parameters surrounded by large uncertainty on the cost-effectiveness. We developed an age structured transmission dyna...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Rozenbaum, M, De Cao, E, Postma, M
Formato:	Journal article
Idioma:	English
Publicado em:	2012

Registos relacionados

Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around....
Por: Rozenbaum, M, et al.
Publicado em: (2012)

Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model.
Por: Robin de Vries, et al.
Publicado em: (2010-01-01)

An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model”
Por: Tu Hong Anh T, et al.
Publicado em: (2013-01-01)

Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
Por: Hak Eelko, et al.
Publicado em: (2011-06-01)

Prior exposure to B. pertussis shapes the mucosal antibody response to acellular pertussis booster vaccination
Por: Evi van Schuppen, et al.
Publicado em: (2022-12-01)

Corrigendum to ‘Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom’
Por: Pauline Versteegen, et al.
Publicado em: (2021-06-01)

Age and Primary Vaccination Background Influence the Plasma Cell Response to Pertussis Booster Vaccination
Por: Annieck M. Diks, et al.
Publicado em: (2022-01-01)

Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis.
Por: Sabine C de Greeff, et al.
Publicado em: (2010-01-01)

Reemergence of Pertussis in the Highly Vaccinated Population of The Netherlands: Observations on Surveillance Data
Por: Hester E. de Melker, et al.
Publicado em: (2000-08-01)

Pertussis in the Netherlands: an Outbreak Despite High Levels of Immunization with Whole-Cell Vaccine
Por: H.E. de Melker, et al.
Publicado em: (1997-06-01)

Underreporting of the 5-year tetanus, diphtheria, pertussis and polio booster vaccination in the Danish Vaccination Register
Por: Sidsel Skou Voss, et al.
Publicado em: (2020-11-01)

Cost-Effectiveness of Pertussis Vaccination Schedule in Israel
Por: Dean Langsam, et al.
Publicado em: (2021-06-01)

Long-Term Immunogenicity upon Pertussis Booster Vaccination in Young Adults and Children in Relation to Priming Vaccinations in Infancy
Por: Pauline Versteegen, et al.
Publicado em: (2022-04-01)

Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination
Por: Saskia van der Lee, et al.
Publicado em: (2018-04-01)

Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries
Por: Pauline Versteegen, et al.
Publicado em: (2022-05-01)

Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands
Por: Joost J.M. Simons, et al.
Publicado em: (2022-08-01)

Pertussis Notification Rate and Tdpa Vaccine/Booster Coverage in Adults: An Opportunity for an Epidemiological Observatory in Primary Care
Por: Francesco Lapi, et al.
Publicado em: (2024-09-01)

Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective?
Por: Anouk T Urbanus, et al.
Publicado em: (2013-01-01)

A system-view of Bordetella pertussis booster vaccine responses in adults primed with whole-cell versus acellular vaccine in infancy
Por: Ricardo da Silva Antunes, et al.
Publicado em: (2021-04-01)

Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters
Por: da Silva Antunes, R, et al.
Publicado em: (2018)

Pertussis vaccines and the role of <I>Bordetella pertussis</I> lipooligosaccharide in the immune response to pertussis infection and vaccination
Por: I. A. Alekseeva, et al.
Publicado em: (2021-03-01)

The Role of the Aceullular Pertussis Vaccine and the Comeback of 'Pertussis Pete'?
Por: John M Conly, et al.
Publicado em: (2001-01-01)

Cost-effectiveness of nonavalent HPV vaccination in the Netherlands
Por: Cody Palmer, et al.
Publicado em: (2024-12-01)

Pertussis toxin neutralizing antibody response after an acellular booster vaccination in Dutch and Finnish participants of different age groups
Por: Aapo Knuutila, et al.
Publicado em: (2022-12-01)

Safety of pertussis vaccines for adolescents
Por: M. P. Kostinov, et al.
Publicado em: (2020-10-01)

New features of pertussis vaccination
Por: A. P. Cherdantsev, et al.
Publicado em: (2020-06-01)

Insights into maternal pertussis vaccination counselling: a qualitative study on perspectives and experiences among midwives and gynaecologists in the Netherlands
Por: Veja Widdershoven, et al.
Publicado em: (2024-09-01)

Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
Por: Hiltsje Hepkema, et al.
Publicado em: (2013-01-01)

Pertussis diagnostic practices of general practitioners in the Netherlands: A survey study
Por: Jeanne Heil, et al.
Publicado em: (2019-10-01)

Pertussis Toxin: A Key Component in Pertussis Vaccines?
Por: Kelsey A. Gregg, et al.
Publicado em: (2019-09-01)

Acellular Pertussis Vaccines and Pertussis Resurgence: Revise or Replace?
Por: Clara Maria Ausiello, et al.
Publicado em: (2014-07-01)

Protective Activity and Safety of Acellular Pertussis Vaccine from Vaccine and Freshly Isolated Strain Bordetella pertussis
Por: E. M. Zaitsev, et al.
Publicado em: (2017-04-01)

A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults
Por: Geert Leroux-Roels, et al.
Publicado em: (2018-01-01)

Circulation of Bordetella pertussis in the Caribbean Netherlands: a population-based seroepidemiological study
Por: Maarten M. Immink, et al.
Publicado em: (2021-10-01)

Systemic priming and intranasal booster with a BcfA-adjuvanted acellular pertussis vaccine generates CD4+ IL-17+ nasal tissue resident T cells and reduces B. pertussis nasal colonization
Por: Kacy S. Yount, et al.
Publicado em: (2023-05-01)

Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines
Por: Punnee Pitisuttithum, et al.
Publicado em: (2021-07-01)

Burden of early, advanced and metastatic breast cancer in The Netherlands
Por: G. T. Vondeling, et al.
Publicado em: (2018-03-01)

Acellular Pertussis Vaccine from Antigens of Freshly Isolated and Vaccine Strains of Bordetella pertussis with Different Genotypic Characteristics
Por: E. M. Zaitsev, et al.
Publicado em: (2021-09-01)

Pertussis, anti-Bordetella pertussis toxin, vaccination, and clinical surveillance
Por: Amnuay Kleebayoon, et al.
Publicado em: (2023-01-01)

Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines
Por: Kevin Markey, et al.
Publicado em: (2019-07-01)